What do systematic reviews say?

Thrombopoietin mimetics vs placebo

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 282 participants
  GRADE not reported

Thrombopoietin mimetics vs placebo

Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.73, 1.27]
  6 studies · 746 participants
  Low

Thrombopoietin mimetics vs placebo

It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.59, 1.77]
  5 studies · 372 participants
  Very low

Thrombopoietin mimetics vs placebo

Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 0.92 [0.86, 0.98]
  5 studies · 390 participants
  Moderate

Thrombopoietin mimetics vs placebo

Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 0.83 [0.66, 1.05]
  4 studies · 358 participants
  Low

Thrombopoietin mimetics vs placebo

The review found no eligible studies for this question.

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thrombopoietin mimetics vs placebo

Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.96, 1.07]
  5 studies · 390 participants
  Moderate

Thrombopoietin mimetics vs placebo

It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).

• Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
  RR 0.89 [0.54, 1.46]
  4 studies · 356 participants
  Very low

G‐CSF vs placebo

It is very uncertain whether G‐CSF changes overall survival compared with placebo (very low certainty).

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  HR 0.8 [0.44, 1.46]
  1 study · 64 participants
  Very low

GM-CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GM-CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GM-CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 118 participants
  Low

GM-CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 149 participants
  Low

GM-CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 111 participants
  Very low

G‐CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 167 participants
  Very low

G‐CSF vs placebo

The review found no eligible studies for this question.

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

G‐CSF vs placebo

• Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low